RxSight (RXST) Research & Development (2020 - 2026)

RxSight has reported Research & Development for 7 years, with the latest figure at $9.5 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 8.63% year-over-year to $9.5 million; the trailing twelve-month figure through Mar 2026 stood at $37.7 million (up 2.59% YoY), and the FY2025 full-year result was $38.5 million, up 12.17% from the prior year.
• Research & Development for Q1 2026 stood at $9.5 million, up from $8.9 million in the prior quarter.
• The five-year high for Research & Development was $10.4 million in Q1 2025, with the low at $6.2 million in Q2 2022.
• Historically, Research & Development has averaged $8.1 million across 5 years, with a median of $8.0 million in 2024.
• Annual changes were most pronounced in 2025 — Research & Development grew 29.09% — and 2026, when it retreated 8.63%.
• RxSight's Research & Development stood at $6.7 million in 2022, then grew by 9.88% to $7.3 million in 2023, then gained by 25.42% to $9.2 million in 2024, then dropped by 3.28% to $8.9 million in 2025, then advanced by 6.37% to $9.5 million in 2026.
• The last three Research & Development figures came in at $9.5 million (Q1 2026), $8.9 million (Q4 2025), and $9.1 million (Q3 2025), per Business Quant data.